Zealand Pharma A-S News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.11.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
07.11.24	Zealand Pharma Announces Financial Results for the First Nine Months of 2024 (GlobeNewswire)
09.10.24	Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism (GlobeNewswire)
08.10.24	Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide (GlobeNewswire)
30.09.24	Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 (GlobeNewswire)
12.09.24	Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
09.09.24	Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide (GlobeNewswire)
30.08.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
30.08.24	Total number of shares and voting rights in Zealand Pharma on August 30, 2024 (GlobeNewswire)
22.08.24	Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
16.08.24	Zealand Pharma major shareholder announcement: Bank of America Corporation (GlobeNewswire)
15.08.24	Zealand Pharma Announces Financial Results for the First Half of 2024 (GlobeNewswire)
28.06.24	Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
28.06.24	Total number of shares and voting rights in Zealand Pharma at June 28, 2024 (GlobeNewswire)
28.06.24	Zealand Pharma completes registration of capital increase (GlobeNewswire)
26.06.24	Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion (GlobeNewswire)
25.06.24	Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion (GlobeNewswire)
25.06.24	Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion (GlobeNewswire)
20.06.24	Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide (GlobeNewswire)
13.06.24	Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
07.06.24	Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis (GlobeNewswire)
06.06.24	Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL (GlobeNewswire)
29.05.24	Zealand Pharma major shareholder announcement: Polar Capital (GlobeNewswire)
23.05.24	Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide (GlobeNewswire)
16.05.24	Zealand Pharma Announces Financial Results for the First Quarter of 2024 (GlobeNewswire)
12.05.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
19.04.24	Correction to Company announcement – No. 23 / 2024 (GlobeNewswire)
19.04.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
19.04.24	Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 (GlobeNewswire)
31.03.24	Total number of shares and voting rights in Zealand Pharma at March 31, 2024 (GlobeNewswire)
26.03.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
26.03.24	Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
21.03.24	Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
20.03.24	Zealand Pharma's Annual General Meeting 2024 (GlobeNewswire)
19.03.24	Zealand Pharma major shareholder announcement: Polar Capital (GlobeNewswire)
19.03.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
13.03.24	New Employee Elected Directors to the Board of Zealand Pharma A/S (GlobeNewswire)
08.03.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
05.03.24	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
05.03.24	Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
27.02.24	Zealand Pharma convenes its Annual General Meeting 2024 (GlobeNewswire)
27.02.24	Zealand Pharma Announces Financial Results for the Full Year 2023 (GlobeNewswire)
26.02.24	Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibro (GlobeNewswire)
31.01.24	Total number of shares and voting rights in Zealand Pharma at January 31, 2024 (GlobeNewswire)
26.01.24	Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
19.01.24	Zealand Pharma major shareholder announcement: J O Hambro Capital Management (GlobeNewswire)
17.01.24	Zealand Pharma major shareholder announcement: J O Hambro Capital Management (GlobeNewswire)
12.01.24	Zealand Pharma completes registration of capital increase (GlobeNewswire)
10.01.24	Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC (GlobeNewswire)
08.01.24	Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Zealand Pharma A-S

Aktien Top/Flop

Meistgelesene Nachrichten